U.S. patent application number 10/915855 was filed with the patent office on 2005-01-20 for combined agents for treatment of glaucoma.
This patent application is currently assigned to SANKYO COMPANY, LIMITED. Invention is credited to Yokoyama, Tomihisa.
Application Number | 20050014808 10/915855 |
Document ID | / |
Family ID | 26576988 |
Filed Date | 2005-01-20 |
United States Patent
Application |
20050014808 |
Kind Code |
A1 |
Yokoyama, Tomihisa |
January 20, 2005 |
Combined agents for treatment of glaucoma
Abstract
A pharmaceutical composition for the prophylaxis or treatment of
glaucoma which comprises an angiotensin II antagonist and
dorzolamide or a pharmacologically acceptable salt thereof, and a
method for the prophylaxis or treatment of glaucoma by
administering the composition to a patient. The angiotensin II
antagonist is of the following formula (I) 1 wherein R.sup.1
represents a structural formula selected from the group consisting
of: 2
Inventors: |
Yokoyama, Tomihisa;
(Saitama-shi, JP) |
Correspondence
Address: |
FRISHAUF, HOLTZ, GOODMAN & CHICK, PC
767 THIRD AVENUE
25TH FLOOR
NEW YORK
NY
10017-2023
US
|
Assignee: |
SANKYO COMPANY, LIMITED
Tokyo
JP
|
Family ID: |
26576988 |
Appl. No.: |
10/915855 |
Filed: |
August 10, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10915855 |
Aug 10, 2004 |
|
|
|
10146747 |
May 16, 2002 |
|
|
|
10146747 |
May 16, 2002 |
|
|
|
PCT/JP00/08545 |
Dec 1, 2000 |
|
|
|
Current U.S.
Class: |
514/381 |
Current CPC
Class: |
A61P 9/12 20180101; A61P
27/06 20180101; A61K 31/535 20130101; A61K 31/55 20130101; A61P
43/00 20180101; A61K 31/415 20130101; A61K 45/06 20130101; Y10S
514/913 20130101; A61K 31/44 20130101; A61K 31/41 20130101; A61K
31/557 20130101; Y10S 514/922 20130101; A61K 31/557 20130101; A61K
31/44 20130101; A61K 31/415 20130101; A61K 31/41 20130101; A61K
31/55 20130101; A61K 31/44 20130101; A61K 31/415 20130101; A61K
31/41 20130101; A61K 31/535 20130101; A61K 31/44 20130101; A61K
31/415 20130101; A61K 31/41 20130101; A61K 31/44 20130101; A61K
31/38 20130101; A61K 31/415 20130101; A61K 31/38 20130101; A61K
31/41 20130101; A61K 31/38 20130101; A61K 31/41 20130101; A61K
2300/00 20130101; A61K 31/415 20130101; A61K 2300/00 20130101; A61K
31/44 20130101; A61K 2300/00 20130101; A61K 31/535 20130101; A61K
2300/00 20130101; A61K 31/55 20130101; A61K 2300/00 20130101; A61K
31/557 20130101; A61K 2300/00 20130101 |
Class at
Publication: |
514/381 |
International
Class: |
A61K 031/4184; A61K
031/4178; A61K 031/41 |
Foreign Application Data
Date |
Code |
Application Number |
Dec 1, 1999 |
JP |
HEI 11-341524 |
Mar 21, 2000 |
JP |
2000-078769 |
Claims
1. A pharmaceutical composition for the prophylaxis or treatment of
glaucoma comprising a pharmaceutically effective amount of (i) an
angiotensin II antagonist of the following formula (I) or a
pharmacologically acceptable salt, ester or other derivative
thereof: 8wherein R.sup.1 represents a structural formula selected
from the group consisting of 9and (ii) dorzolamide or a
pharmacologically acceptable salt thereof, either alone or in
combination with a pharmaceutically acceptable carrier.
2. The pharmaceutical composition for the prophylaxis or treatment
of glaucoma according to claim 1, wherein a ratio of the
angiotensin II antagonist (i) to the dorzolamide or
pharmacologically acceptable salt thereof (ii) is 1:1 to 10:1.
3. The pharmaceutical composition for the prophylaxis or treatment
of glaucoma according to claim 1, wherein R.sup.1 represents a
structural formula having the formula (Ia).
4. The pharmaceutical composition for the prophylaxis or treatment
of glaucoma according to claim 1, wherein R.sup.1 represents a
structural formula having the formula (1b).
5. The pharmaceutical composition for the prophylaxis or treatment
of glaucoma according to claim 1, wherein R.sup.1 represents a
structural formula having the formula (1c).
6. The pharmaceutical composition for the prophylaxis or treatment
of glaucoma according to claim 1, wherein said (ii) is dorzolamide
hydrochloride.
7. The pharmaceutical composition for the prophylaxis or treatment
of glaucoma according to claim 1, which is in a form suitable for
topical administration to the eyes.
8. A method for preventing or treating glaucoma comprising
administering to a warm blooded animal in need thereof the
pharmaceutical composition for the prophylaxis or treatment of
glaucoma according to claim 1.
9. A method for preventing glaucoma comprising administering to a
human in need thereof the pharmaceutical composition for the
prophylaxis or treatment of glaucoma according to claim 1.
10. A method for preventing glaucoma comprising administering to a
human in need thereof the pharmaceutical composition for the
prophylaxis or treatment of glaucoma according to claim 2.
11. A method for preventing glaucoma comprising administering to a
human in need thereof the pharmaceutical composition for the
prophylaxis or treatment of glaucoma according to claim 3.
12. A method for preventing glaucoma comprising administering to a
human in need thereof the pharmaceutical composition for the
prophylaxis or treatment of glaucoma according to claim 4.
13. A method for preventing glaucoma comprising administering to a
human in need thereof the pharmaceutical composition for the
prophylaxis or treatment of glaucoma according to claim 5.
14. A method for preventing glaucoma comprising administering to a
human in need thereof the pharmaceutical composition for the
prophylaxis or treatment of glaucoma according to claim 6.
15. A method for preventing glaucoma comprising administering to a
human in need thereof the pharmaceutical composition for the
prophylaxis or treatment of glaucoma according to claim 7.
16. A method for treating glaucoma comprising administering to a
human in need thereof the pharmaceutical composition for the
prophylaxis or treatment of glaucoma according to claim 1.
17. A method for treating glaucoma comprising administering to a
human in need thereof the pharmaceutical composition for the
prophylaxis or treatment of glaucoma according to claim 2.
18. A method for treating glaucoma comprising administering to a
human in need thereof the pharmaceutical composition for the
prophylaxis or treatment of glaucoma according to claim 3.
19. A method for treating glaucoma comprising administering to a
human in need thereof the pharmaceutical composition for the
prophylaxis or treatment of glaucoma according to claim 4.
20. A method for treating glaucoma comprising administering to a
human in need thereof the pharmaceutical composition for the
prophylaxis or treatment of glaucoma according to claim 5.
21. A method for treating glaucoma comprising administering to a
human in need thereof the pharmaceutical composition for the
prophylaxis or treatment of glaucoma according to claim 6.
22. A method for treating glaucoma comprising administering to a
human in need thereof the pharmaceutical composition for the
prophylaxis or treatment of glaucoma according to claim 7.
23. A method for preventing or treating glaucoma comprising
administering to a warm blooded animal a pharmaceutically effective
amount of active ingredients, the active ingredients comprising (i)
an angiotensin II antagonist of the following formula (I) or a
pharmacologically acceptable salt, ester or other derivative
thereof: 10, wherein R.sup.1 represents a structural formula
selected from the group consisting of 11and (ii) dorzolamide or a
pharmacologically acceptable salt thereof, the active ingredients
(i) and (ii) being administered simultaneously, separately or
successively.
24. The method according to claim 23, wherein the warm blooded
animal is a human.
25. The method according to claim 24, wherein the method is for
treating glaucoma.
26. The method according to claim 23, wherein the method is for
preventing glaucoma.
27. The method according to claim 23, wherein R.sup.1 is of the
formula (Ia).
28. The method according to claim 23, wherein R.sup.1 is of the
formula (Ib).
29. The method according to claim 23, wherein R.sup.1 is of the
formula (Ic).
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional application of application
Ser. No. 10/146,747 filed May 16, 2002, which is a
continuation-in-part application of International Application No.
PCT/JP00/08545 filed Dec. 1, 2000.
FIELD OF THE INVENTION
[0002] The present invention relates to a prophylactic or
therapeutic agent (pharmaceutical composition) for glaucoma having
excellent intraocular pressure lowering action and a method for
preventing or treating glaucoma by administering the composition to
a patient.
BACKGROUND OF THE INVENTION
[0003] .beta.-Blockers (timolol maleate, carteolol, etc.),
prostaglandin type compounds (isopropyl unoprostone and
latanoprost) and a carbonic anhydrase inhibitor (dorzolamide
hydrochloride) have been mainly used as agents for the treatment of
glaucoma. Moreover, an .alpha.1-blocker (bunazosin hydrochloride)
and an .alpha..beta.-blocker (nipradilol) are now at the stage of
clinical trials or application for approval.
[0004] There are reports (for example, EP795326, EP631780,
WO95/21609, WO91/15206, etc.) that angiotensin II antagonists are
useful agents for the treatment of glaucoma. Among angiotensin II
antagonists, only CGP48933 has been subjected to clinical trial. It
was reported that its effect for glaucoma was insufficient (Eur. J.
Ophthalmol. 1997, January-March; 7(1): 35-9) and the development of
it has been stopped since then.
SUMMARY OF THE INVENTION
[0005] The present inventors have carried out an extensive
investigation on the preparation of agents for the prophylaxis or
treatment of glaucoma having superior intraocular pressure lowering
effect and on their pharmacological action. As a result, it has
been found that an intraocular pressure lowering action can be
potentiated by using an angiotensin II antagonist in combination
with at least one compound selected from adrenaline receptor
blockers, prostaglandins and carbonic anhydrase inhibitors, leading
to the completion of the present invention.
[0006] The present invention relates to the following:
[0007] (1) an agent for the prophylaxis or treatment of glaucoma,
which comprises an angiotensin II antagonist and at least one
compound selected from adrenaline receptor blockers, prostaglandins
and carbonic anhydrase inhibitors as active ingredients for
simultaneous, separate or successive use of these active
ingredients.
[0008] Of these agents, especially preferred are the following:
[0009] (2) an agent for the prophylaxis or treatment of glaucoma,
wherein the angiotensin II antagonist is a compound having the
below-described formula (1) or a pharmacologically acceptable salt,
ester or other derivative thereof: 3
[0010] wherein, R.sup.1 represents a group having the
below-described structural formula (Ia), (Ib), (IC), (Id), (Ie) or
(If): 4
[0011] (3) an agent for the prophylaxis or treatment of glaucoma as
described in (2), wherein R.sup.1 represents a group having the
formula (Ia), (Ib) or (Ic),
[0012] (4) an agent for the prophylaxis or treatment of glaucoma as
described in (2), wherein R.sup.1 represents a group having the
formula (Ia),
[0013] (5) an agent for the prophylaxis or treatment of glaucoma,
wherein the adrenaline receptor blocker is bunazosin, timolol or
nipradilol, or a pharmacologically acceptable salt or ester
thereof,
[0014] (6) an agent for the prophylaxis or treatment of glaucoma,
wherein the adrenaline receptor blocker is bunazosin hydrochloride,
timolol maleate or nipradilol,
[0015] (7) an agent for the prophylaxis or treatment of glaucoma,
which comprises an angiotensin II antagonist and at least one
compound selected from prostaglandins and carbonic anhydrase
inhibitors as active ingredients for simultaneous, separate or
successive use thereof,
[0016] (8) an agent for the prophylaxis or treatment of glaucoma,
wherein the prostaglandin is isopropyl unoprostone or latanoprost,
or a pharmacologically acceptable salt thereof,
[0017] (9) an agent for the prophylaxis or treatment of glaucoma,
wherein the prostaglandin is isopropyl unoprostone or
latanoprost,
[0018] (10) an agent for the prophylaxis or treatment of glaucoma,
wherein the carbonic anhydrase inhibitor is dorzolamide or a
pharmacologically acceptable salt thereof,
[0019] (11) an agent for the prophylaxis or treatment of glaucoma,
wherein the carbonic anhydrase inhibitor is dorzolamide
hydrochloride, and
[0020] (12) an agent for the prophylaxis or treatment of glaucoma
as described in any one selected from (1) to (11) above, which is
in a form suitable for topical application to the eyes.
[0021] The present invention also relates to:
[0022] (13) a method for preventing or treating glaucoma, which
comprises administering an agent for the prophylaxis or treatment
of glaucoma as described in any one selected from (1) to (11)
above.
DETAILED DESCRIPTION OF THE INVENTION
[0023] In the present invention,
[0024] the term "angiotensin II antagonist" means a compound which
exhibits antagonism against angiotensin II in an angiotensin II
receptor, thereby weakening the action of angiotensin II. Compounds
capable of inhibiting over 50% of the function of angiotensin II at
a concentration of 1 .mu.M are preferred, of which angiotensin II
selective antagonists are more preferred. Especially preferred as
"angiotensin II antagonists" are the compounds of the following
formula (I) or pharmacologically acceptable salts thereof, or
esters thereof or other derivatives thereof: 5
[0025] wherein R.sup.1 represents the following structural formula
(Ia), (Ib), (Ic), (Id), (Ie) or (If): 6
[0026] Of the above-described compounds of formula (I), preferred
are the compounds having a group of formula (Ia), (Ib) or (Ic) as
R.sup.1, of which the compounds having a group of formula (Ia) as
R.sup.1 are especially preferred.
[0027] The term "adrenaline receptor blocker" as used herein means
one of .alpha.-blockers, .beta.-blockers and
.alpha..beta.-blockers. Preferred as the .alpha.-blocker are
.alpha.1-blockers, of which bunazosin or a pharmacologically
acceptable salt thereof is especially preferred, with bunazosin
hydrochloride being most preferred. Especially preferred as the
.beta.-blocker is timolol or a pharmacologically acceptable salt
thereof or an ester thereof, of which timolol maleate is most
preferred. Especially preferred as the .alpha..beta.-blocker is
nipradilol or a pharmacologically acceptable salt thereof or an
ester thereof, of which nipradilol is most preferred.
[0028] The term "prostaglandin" means any one of naturally existing
prostaglandins such as prostaglandin F2.alpha. or prostaglandin
derivatives such as isopropyl unoprostone and latanoprost, or a
pharmacologically acceptable salt thereof. Of these, isopropyl
unoprostone or latanoprost, or a pharmacologically acceptable salt
thereof is especially preferred, of which isopropyl unoprostone or
latanoprost is most preferred.
[0029] As the "carbonic anhydrase inhibitor", dorzolamide or a
pharmacologically acceptable salt thereof is especially preferred,
of which dorzolamide hydrochloride is most preferred.
[0030] The term "pharmacologically acceptable salt" means a salt,
which can be formed when the "angiotensin II antagonist",
"adrenaline receptor blocker", "prostaglandin" and/or "carbonic
anhydrase inhibitor" has an acidic group such as carboxyl or a
basic group such as amino or imino.
[0031] Preferred examples of the salt formed with an acidic group
include alkali metal salts such as a sodium salt, potassium salt or
lithium salt, alkaline earth metal salts such as a calcium salt or
magnesium salt, metal salts such as an aluminum salt or iron salt;
amine salts, e.g., inorganic salts such as an ammonium salt and
organic salts such as a t-octylamine salt, dibenzylamine salt,
morpholine salt, glucosamine salt, phenylglycine alkyl ester salt,
ethylenediamine salt, N-methylglucamine salt, guanidine salt,
diethylamine salt, triethylamine salt, dicyclohexylamine salt,
N,N'-dibenzylethylenediamine salt, chloroprocaine salt, procaine
salt, diethanolamine salt, N-benzylphenethylamine salt, piperazine
salt, tetramethylammonium salt or tris(hydroxymethyl)aminometh- ane
salt; and amino acid salts such as a glycine salt, lysine salt,
arginine salt, ornithine salt, glutamate or aspartate.
[0032] Preferred examples of the salt formed with a basic group
include hydro-halides such as a hydrofluoride, hydrochloride,
hydrobromide or hydroiodide, inorganic acid salts such as a
nitrate, perchlorate, sulfate or phosphate; lower alkanesulfonates
such as a methanesulfonate, trifluoromethanesulfonate or
ethanesulfonate, arylsulfonates such as a benzenesulfonate or
p-toluenesulfonate, organic acid salts such as an acetate, malate,
fumarate, succinate, citrate, ascorbate, tartrate, oxalate or
maleate; and amino acid salts such as a glycine salt, lysine salt,
arginine salt, ornithine salt, glutamate or aspartate.
[0033] When a "pharmacologically acceptable salt" is allowed to
stand in the atmosphere or is recrystallized, it sometimes absorbs
water to form a hydrate.
[0034] Such a hydrate is also embraced in the present
invention.
[0035] The term "ester or other derivative" means a compound which
is produced by modifying a functional group (e.g. hydroxyl,
carboxyl, amino or the like group) of the "angiotensin II
antagonist" with a protecting group in a manner known per se in the
art, and is a derivative converted into an "angiotensin II
antagonist" by administration to the living body. By administering
the compound intravenously, orally or in eye drops to experimental
animals such as rats or mice, examining their body fluids and
confirming the angiotensin II antagonism of the compound thus
detected, the compound can be determined whether it is such a
derivative or not.
[0036] Examples of the "ester" include "esters formed with a
hydroxyl group" and "esters formed with a carboxyl group". The term
"ester" means an ester whose ester residue is a "conventional
protecting group" or a "protecting group removable in vivo by a
biological method such as hydrolysis".
[0037] The term "conventional protecting group" means a protecting
group removable by a chemical method such as hydrogenolysis,
hydrolysis, electrolysis or photolysis.
[0038] Preferred examples of the "conventional protecting group"
related to the "ester formed with a hydroxyl group" include
"aliphatic acyl groups" (preferably, lower aliphatic C.sub.1-6 acyl
groups), for example, alkanoyl groups such as a formyl, acetyl,
propionyl, butyryl, isobutyryl, pentanoyl, pivaloyl, valeryl,
isovaleryl, octanoyl, nonanoyl, decanoyl, 3-methylnonanoyl,
8-methylnonanoyl, 3-ethyloctanoyl, 3,7-dimethyloctanoyl,
undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl,
hexadecanoyl, 1-methylpentadecanoyl, 14-methylpentadecanoyl,
13,13-dimethyltetradecanoyl, heptadecanoyl, 15-methylhexadecanoyl,
octadecanoyl, 1-methylheptadecanoyl, nonadecanoyl, eicosanoyl or
heneicosanoyl group, halogeno-- alkylcarbonyl groups such as a
chloroacetyl, dichloroacetyl, trichloroacetyl or trifluoroacetyl
group, lower alkoxyalkylcarbonyl groups such as a methoxyacetyl
group, and unsaturated alkylcarbonyl groups such as an acryloyl,
propioloyl, methacryloyl, crotonoyl, isocrotonoyl or
(E)-2-methyl-2-butenoyl group; "aromatic acyl groups", for example,
arylcarbonyl groups such as a benzoyl, .alpha.-naphthoyl or
.beta.-naphthoyl group, halogeno-arylcarbonyl groups such as a
2-bromobenzoyl or 4-chlorobenzoyl group, lower alkylated
arylcarbonyl groups such as a 2,4,6-trimethylbenzoyl or 4-toluoyl
group, lower alkoxylated arylcarbonyl groups such as a 4-anisoyl
group, nitrated arylcarbonyl groups such as a 4-nitrobenzoyl or
2-nitrobenzoyl group, lower alkoxycarbonylated arylcarbonyl groups
such as a 2-(methoxycarbonyl)benzoyl group, and arylated
arylcarbonyl groups such as a 4-phenylbenzoyl group;
"alkoxycarbonyl groups", for example, lower alkoxycarbonyl groups
such as a methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,
butoxycarbonyl, s-butoxycarbonyl, t-butoxycarbonyl or
isobutoxycarbonyl group, and lower alkoxycarbonyl groups
substituted with a halogen or tri(lower alkyl)silyl group such as a
2,2,2-trichloroethoxycarbonyl or 2-trimethylsilylethoxyca- rbonyl
group; "tetrahydropyranyl or tetrahydrothiopyranyl groups" such as
a tetrahydropyran-2-yl, 3-bromotetrahydropyran-2-yl,
4-methoxytetrahydropyran-4-yl, tetrahydrothiopyran-2-yl or
4-methoxytetrahydrothiopyran-4-yl group; "tetrahydrofuranyl or
tetrahydrothiofuranyl groups" such as a tetrahydrofuran-2-yl or
tetrahydrothiofuran-2-yl group; "silyl groups", for example,
tri(lower alkyl)silyl groups such as a trimethylsilyl,
triethylsilyl, isopropyldimethylsilyl, t-butyldimethylsilyl,
methyldiisopropylsilyl, methyldi-t-butylsilyl or triisopropylsilyl
group, and tri(lower alkyl)silyl groups substituted with one or two
aryl groups such as a diphenylmethylsilyl, diphenylbutylsilyl,
diphenylisopropylsilyl or phenyldiisopropylsilyl group;
"alkoxymethyl groups", for example, lower alkoxymethyl groups such
as a methoxymethyl, 1,1-dimethyl-1-methoxymethyl- , ethoxymethyl,
propoxymethyl, isopropoxymethyl, butoxymethyl or t-butoxymethyl
group, lower alkoxylated (lower alkoxy)methyl groups such as a
2-methoxyethoxymethyl group and halogeno(lower alkoxy)methyl groups
such as a 2,2,2-trichloroethoxymethyl or bis(2-chloroethoxy)methyl
group; "substituted ethyl groups", for example, lower alkoxylated
ethyl groups such as a 1-ethoxyethyl or 1-(isopropoxy)ethyl group
and halogenated ethyl groups such as a 2,2,2-trichloroethyl group;
"aralkyl groups", for example, lower alkyl groups substituted with
1 to 3 aryl groups such as a benzyl, .alpha.-naphthylmethyl,
.beta.-naphthylmethyl, diphenylmethyl, triphenylmethyl,
.alpha.-naphthyldiphenylmethyl or 9-anthrylmethyl group and lower
alkyl groups substituted with 1 to 3 aryl groups having an aryl
ring substituted with a lower alkyl, lower alkoxy, nitro, halogen
or cyano group such as a 4-methylbenzyl, 2,4,6-trimethylbenzyl,
3,4,5-trimethylbenzyl, 4-methoxybenzyl,
4-methoxyphenyldiphenylmethyl, 2-nitrobenzyl, 4-nitrobenzyl,
4-chlorobenzyl, 4-bromobenzyl or 4-cyanobenzyl group;
"alkenyloxycarbonyl groups" such as a vinyloxycarbonyl or
allyloxycarbonyl group; and "aralkyloxycarbonyl groups" which may
have an aryl ring substituted by 1 or 2 lower alkoxy or nitro
groups such as a benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl,
3,4-dimethoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl or
4-nitrobenzyloxycarbonyl group.
[0039] Preferred examples of the "conventional protecting group"
related to the "ester formed with a carboxyl group" include lower
alkyl groups such as a methyl, ethyl, n-propyl, isopropyl, n-butyl,
isobutyl, s-butyl, tert-butyl, n-pentyl, isopentyl, 2-methylbutyl,
neopentyl, 1-ethylpropyl, n-hexyl, isohexyl, 4-methylpentyl,
3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl,
2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl,
1,3-dimethylbutyl, 2,3-dimethylbutyl or 2-ethylbutyl group; lower
alkenyl groups such as an ethenyl, 1-propenyl, 2-propenyl,
1-methyl-2-propenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl,
2-methyl-2-propenyl, 2-ethyl-2-propenyl, 1-butenyl, 2-butenyl,
1-methyl-2-butenyl, 1-methyl-1-butenyl, 3-methyl-2-butenyl,
1-ethyl-2-butenyl, 3-butenyl, 1-methyl-3-butenyl,
2-methyl-3-butenyl, 1-ethyl-3-butenyl, 1-pentenyl, 2-pentenyl,
1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-pentenyl,
1-methyl-3-pentenyl, 2-methyl-3-pentenyl, 4-pentenyl,
1-methyl-4-pentenyl, 2-methyl-4-pentenyl, 1-hexenyl, 2-hexenyl,
3-hexenyl, 4-hexenyl or 5-hexenyl group; lower alkynyl groups such
as an ethynyl, 2-propynyl, 1-methyl-2-propynyl,
2-methyl-2-propynyl, 2-ethyl-2-propynyl, 2-butynyl,
1-methyl-2-butynyl, 2-methyl-2-butynyl, 1-ethyl-2-butynyl,
3-butynyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl,
1-ethyl-3-butynyl, 2-pentynyl, 1-methyl-2-pentynyl,
2-methyl-2-pentynyl, 3-pentynyl, 1-methyl-3-pentynyl,
2-methyl-3-pentynyl, 4-pentynyl, 1-methyl-4-pentynyl,
2-methyl-4-pentynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl or 5-hexynyl
group; halogeno(lower alkyl) groups such as a trifluoromethyl,
trichloromethyl, difluoromethyl, dichloromethyl, dibromomethyl,
fluoromethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl,
2-bromoethyl, 2-chloroethyl, 2-fluoroethyl, 2-iodoethyl,
3-chloropropyl, 4-fluorobutyl, 6-iodohexyl or 2,2-dibromoethyl
group; hydroxy("lower alkyl groups") such as a 2-hydroxyethyl,
2,3-dihydroxypropyl, 3-hydroxypropyl, 3,4-dihydroxybutyl or
4-hydroxybutyl group; "lower aliphatic acyl"-"lower alkyl groups"
such as an acetylmethyl group; the above-exemplified "aralkyl
groups"; and the above-exemplified "silyl groups".
[0040] The term "protecting group removable in vivo by a biological
method such as hydrolysis" means a protecting group removable in
vivo by a biological method such as hydrolysis to produce a free
acid or its salt. In order to determine whether a compound is such
a derivative or not, one can administer the compound by intravenous
injection to experimental animals such as rats or mice, followed by
examination of their body fluids to confirm the angiotensin II
antagonism of the compound thus detected.
[0041] Preferred examples of the "protecting group removable in
vivo by a biological method such as hydrolysis" related to the
"ester formed with a hydroxyl group" include "carbonyloxyalkyl
groups" which are 1-(acyloxy)-"lower alkyl groups", for example,
1-("lower aliphatic acyl"oxy)-"lower alkyl groups" such as a
formyloxymethyl, acetoxymethyl, dimethylaminoacetoxymethyl,
propionyloxymethyl, butyryloxymethyl, pivaloyloxymethyl,
valeryloxymethyl, isovaleryloxymethyl, hexanoyloxymethyl,
1-formyloxyethyl, 1-acetoxyethyl, 1-propionyloxyethyl,
1-butyryloxyethyl, 1-pivaloyloxyethyl, 1-valeryloxyethyl,
1-isovaleryloxyethyl, 1-hexanoyloxyethyl, 1-formyloxypropyl,
1-acetoxypropyl, 1-propionyloxypropyl, 1-butyryloxypropyl,
1-pivaloyloxypropyl, 1-valeryloxypropyl, 1-isovaleryloxypropyl,
1-hexanoyloxypropyl, 1-acetoxybutyl, 1-propionyloxybutyl,
1-butryloxybutyl, 1-pivaloyloxybutyl, 1-acetoxypentyl,
1-propionyloxypentyl, 1-butryloxypentyl, 1-pivaloyloxypentyl or
1-pivaloyloxyhexyl group, 1-("cycloalkyl"carbonyloxy)-"lower alkyl
groups" such as a cyclopentylcarbonyloxymethyl,
cyclohexylcarbonyloxymeth- yl, 1-cyclopentylcarbonyloxyethyl,
1-cyclohexylcarbonyloxyethyl, 1-cyclopentylcarbonyloxypropyl,
1-cyclohexylcarbonyloxypropyl, 1-cyclopentylcarbonyloxybutyl or
1-cyclohexylcarbonyloxybutyl group, and 1-("aromatic
acyl"oxy)-"lower alkyl groups" such as a benzoyloxymethyl group;
(lower alkoxycarbonyloxy)alkyl groups such as a
methoxycarbonyloxymethyl, ethoxycarbonyloxymethyl,
propoxycarbonyloxymethyl, isopropoxycarbonyloxymethyl,
butoxycarbonyloxymethyl, isobutoxycarbonyloxymethyl,
pentyloxycarbonyloxymethyl, hexyloxycarbonyloxymethyl,
cyclohexyloxycarbonyloxymethyl,
cyclohexyloxycarbonyloxy(cyclohexyl)methy- l,
1-(methoxycarbonyloxy)ethyl, 1-(ethoxycarbonyloxy)ethyl,
1-(propoxycarbonyloxy)ethyl, 1-(isopropoxycarbonyloxy)ethyl,
1-(butoxycarbonyloxy)ethyl, 1-(isobutoxycarbonyloxy)ethyl,
1-(t-butoxycarbonyloxy)ethyl, 1-(pentyloxycarbonyloxy)ethyl,
1-(hexyloxycarbonyloxy)ethyl, 1-(cyclopentyloxycarbonyloxy)ethyl,
1-(cyclopentyloxycarbonyloxy)propyl,
1-(cyclohexyloxycarbonyloxy)propyl,
1-(cyclopentyloxycarbonyloxy)butyl,
1-(cyclohexyloxycarbonyloxy)butyl,
1-(cyclohexyloxycarbonyloxy)ethyl, 1-(ethoxycarbonyloxy)propyl,
1-(methoxycarbonyloxy)propyl, 1-(ethoxycarbonyloxy)propyl,
1-(propoxycarbonyloxy)propyl, 1-(isopropoxycarbonyloxy)propyl,
1-(butoxycarbonyloxy)propyl, 1-(isobutoxycarbonyloxy)propyl,
1-(pentyloxycarbonyloxy)propyl, 1-(hexyloxycarbonyloxy)propyl,
1-(methoxycarbonyloxy)butyl, 1-(ethoxycarbonyloxy)butyl,
1-(propoxycarbonyloxy)butyl, 1-(isopropoxycarbonyloxy)butyl,
1-(butoxycarbonyloxy)butyl, 1-(isobutoxycarbonyloxy)butyl,
1-(methoxycarbonyloxy)pentyl, 1-(ethoxycarbonyloxy)pentyl,
1-(methoxycarbonyloxy)hexyl or 1-(ethoxycarbonyloxy)hexyl
group;
[0042] oxodioxolenylmethyl groups such as a
(5-phenyl-2-oxo-1,3-dioxolen-4- -yl)methyl,
[5-(4-methylphenyl)-2-oxo-1,3-dioxolen-4-yl]methyl,
[5-(4-methoxyphenyl)-2-oxo-1,3-dioxolen-4-yl]methyl,
[5-(4-fluorophenyl)-2-oxo-1,3-dioxolen-4-yl]methyl,
[5-(4-chlorophenyl)-2-oxo-1,3-dioxolen-4-yl]methyl,
(2-oxo-1,3-dioxolen-4-yl)methyl,
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl- ,
(5-ethyl-2-oxo-1,3-dioxolen-4-yl)methyl,
(5-propyl-2-oxo-1,3-dioxolen-4-- yl)methyl,
(5-isopropyl-2-oxo-1,3-dioxolen-4-yl)methyl or
(5-butyl-2-oxo-1,3-dioxolen-4-yl)methyl group; "phthalidyl groups"
such as a phthalidyl, dimethylphthalidyl or dimethoxyphthalidyl
group; the above-exemplified "lower aliphatic acyl groups"; the
above-exemplified "aromatic acyl groups"; "half ester salt residues
of succinic acid"; "phosphate ester salt residues"; "amino acids
and the like residues capable of forming an ester"; a carbamoyl
group; a carbamoyl group substituted by 1 or 2 lower alkyl groups;
and "1-(acyloxy)alkyloxycarbony- l groups" such as a
pivaloyloxymethyloxycarbonyl group, of which the "carbonyloxyalkyl
groups" are preferred.
[0043] Preferred examples of the "protecting group removable in
vivo by a biological method such as hydrolysis" related to the
"ester formed with a carboxyl group" include "alkoxy(lower alkyl)
groups", for example, (lower alkoxy)(lower alkyl) groups such as a
methoxymethyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl,
1-(isopropoxy)ethyl, 2-methoxyethyl, 2-ethoxyethyl,
1,1-dimethyl-1-methoxymethyl, ethoxymethyl, n-propoxymethyl,
isopropoxymethyl, n-butoxymethyl or t-butoxymethyl group, lower
alkoxylated (lower alkoxy)(lower alkyl) groups such as a
2-methoxyethoxymethyl group, "aryl"oxy("lower alkyl groups ") such
as a phenoxymethyl group, and halogenated (lower alkoxy)(lower
alkyl) groups such as a 2,2,2-trichloroethoxymethyl or
bis(2-chloroethoxy)methyl group; ""lower alkoxy"carbonyl"lower
alkyl groups" " such as a methoxycarbonylmethyl group; "cyano"lower
alkyl groups" " such as a cyanomethyl or 2-cyanoethyl group;
""lower alkyl"thiomethyl groups" such as a methylthiomethyl or
ethylthiomethyl group; ""aryl"thiomethyl groups" such as a
phenylthiomethyl or naphthylthiomethyl group; ""lower
alkyl"sulfonyl"lower alkyl groups" which may be substituted by
halogen" such as a 2-methanesulfonylethyl or
2-trifluoromethanesulfonylethyl group; ""aryl"sulfonyl"lower alkyl
groups" " such as a 2-benzenesulfonylethyl or
2-toluenesulfonylethyl group; the above-exemplified
"1-(acyloxy)-"lower alkyl" groups"; the above-exemplified
"phthalidyl groups"; aryl groups such as a phenyl or indanyl group;
the above-exemplified "lower alkyl groups"; "carboxylalkyl groups"
such as a carboxymethyl group; and "amino acids and the like
residues capable of forming an amide" such as a phenylalanine
group.
[0044] The term "other derivative" means a derivative of the above
compound of formula (I) other than the above-described "ester" or
the above-described "pharmacologically acceptable salt" which can
be formed, if it has an amino and/or carboxyl group. Amide
derivatives are such a derivative.
[0045] As for the prophylactic and therapeutic agent for glaucoma
according to the present invention, angiotensin II antagonists as
disclosed, for example, in EP795326, EP631780 (U.S. Pat. No.
5,250,521), WO95/21609 and WO91/15206 can be employed. These
compounds can be prepared readily by a known process.
[0046] As for the "adrenaline receptor blocker", compounds as
disclosed, for example, in GB1253710, GB1398455 and EP42299 can be
employed. These compounds can be prepared readily by a known
process.
[0047] As for the "prostaglandin", compounds as disclosed, for
example, in EP289349 and WO90/2533 can be employed. These compounds
can be prepared readily by a known process.
[0048] As for the "carbonic anhydrase inhibitor", compounds as
disclosed, for example, in EP296879 can be employed and they can be
prepared readily by a known process.
[0049] The entire contents of each of the following above described
publications are hereby incorporated by reference herein: EP795326,
EP631780, U.S. Pat. No. 5,250,521, WO95/21609, WO91/15206,
GB1253710, GB1398455, EP42299, EP289349, WO90/2533 and
EP296879.
[0050] In the prophylactic and therapeutic agent for glaucoma
according to the present invention, a pharmaceutical composition
for simultaneous use of the angiotensin II antagonist and at least
one compound selected from the adrenaline receptor blockers,
prostaglandins and carbonic anhydrase inhibitors can be prepared in
a manner known per se in the art by using compounds serving as
active ingredients (more specifically, an angiotensin II antagonist
and at least one compound selected from the adrenaline receptor
blockers, prostaglandins and carbonic anhydrase inhibitors). This
pharmaceutical composition is preferably prepared in a form suited
for topical application to the eyes, for example, eye drops such as
aqueous ophthalmic solutions, aqueous ophthalmic suspensions,
non-aqueous ophthalmic solutions and non-aqueous ophthalmic
suspensions, gels, and ophthalmic ointments. Upon formulation, a
pharmacologically acceptable carrier can be used. No particular
limitation is imposed on the carrier usable here insofar as it is
ordinarily employed for the preparation of ophthalmic formulations.
Examples of the carriers include inert diluents, preservatives,
isotonic agents, buffers, stabilizers, pH regulators, thickeners,
surfactants and ointment bases.
[0051] Examples of the inert diluent include aqueous solvents such
as water, Ringer's solution and isotonic saline solution and oil
solvents such as castor oil, olive oil, sesame oil, soybean oil,
liquid paraffin, propylene glycol and .beta.-octyldodecanol.
[0052] Examples of the preservative include parabens such as
methylparaben, ethylparaben, propylparaben and butylparaben,
benzalkonium chloride, chlorhexidine, benzethonium chloride, benzyl
alcohol, sorbic acid and salt thereof, thimerosal and
chlorobutanol, of which the parabens, benzalkonium chloride and
benzethonium chloride are preferred.
[0053] Examples of the isotonic agent include sodium chloride,
mannitol, sorbitol and glycerin.
[0054] Examples of the buffer include boric acid, borates,
phosphates, acetates and citrates.
[0055] Examples of the stabilizer include ethylenediamine
tetraacetate.
[0056] Examples of the pH regulator include hydrochloric acid,
acetic acid and sodium hydroxide.
[0057] Examples of the ointment base include vaseline, plastibase
and liquid paraffin.
[0058] Examples of the thickener include methyl cellulose,
carmellose and salts thereof, hydroxyethyl cellulose, sodium
alginate, carboxyvinyl polymer and polyvinylpyrrolidone.
[0059] Examples of the surfactant include polyethylene glycol,
propylene glycol, polyoxyethylene hydrogenated castor oil and
Polysorbate.
[0060] For the preparation of a gel, carboxyvinyl polymer, methyl
cellulose, sodium alginate, hydroxypropyl cellulose or ethylene
maleic anhydride polymer are usable.
[0061] The above-described pharmaceutical composition can contain
compounds serving as active ingredients at a concentration ranging
from the lower limit of 0.001 volume % (preferably 0.01 volume %)
to the upper limit of 10 volume % (preferably 5 volume %). The
"concentration" refers to one of the active ingredients, that is,
it could be (i) the concentration of the angiotensin II in the
present composition or it could be the concentration of (ii) the at
least one compound selected from the group consisting of an
adrenaline receptor blocker, a prostaglandin and a carbonic
inhibitor. The "concentration" does not refer to both active
ingredients.
[0062] Ratios of the active ingredients, i.e., ratios of (i) the
angiotensin II antagonist to (ii) the at least one compound
selected from the group consisting of an adrenaline receptor
blocker, a prostaglandin and a carbonic anhydrase inhibitor, are as
follows: when (ii) is an adrenaline receptor blocker, the ratio
(i): (ii) is from 10:1 to 100:1; when (ii) is a prostaglandin, the
ratio (i): (ii) is from 100:1 to 1000:1; when (ii) is a carbonic
inhibitor, the ratio (i): (ii) is from 1:1 to 10:1.
[0063] Although the dose of the pharmaceutical composition varies
depending on the symptom or the like, it can be administered by one
to several drops, preferably 1 to 2 drops (one drop amounts to
about 50 .mu.L) at a time, once or in about 6 times a day.
[0064] The above-described pharmaceutical composition can also be
prepared, for example, in the form suitable for oral administration
such as tablets, capsules, granules, powders or syrups or for
parenteral administration such as injection or suppository. These
formulations can be prepared by well known methods using additives
such as excipients (examples include organic excipients, e.g.,
sugar derivatives such as lactose, sucrose, glucose, mannitol and
sorbitol, starch derivatives such as corn starch, potato starch,
.alpha.-starch, dextrin and carboxymethyl starch, cellulose
derivatives such as crystalline cellulose, low substituted
hydroxypropyl cellulose, hydroxypropylmethyl cellulose,
carboxymethyl cellulose, calcium carboxymethyl cellulose and sodium
internally-cross-linked carboxymethyl cellulose, acacia, dextran,
and Pullulan; and inorganic excipients, e.g., silicate derivatives
such as light silicic anhydride, synthetic aluminum silicate and
magnesium metasilicate aluminate, phosphates such as calcium
phosphate, carbonates such as calcium carbonate, and sulfates such
as calcium sulfate); lubricants (examples include stearic acid,
metal stearates such as calcium stearate and magnesium stearate,
talc, colloidal silica, waxes such as beeswax and spermaceti, boric
acid, adipic acid, sulfates such as sodium sulfate, glycol, fumaric
acid, sodium benzoate, DL-leucine, sodium salts of fatty acids,
lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl
sulfate; silicic acids such as silicic anhydride and silicic acid
hydrate, and the above-exemplified starch derivatives); binders
(examples include polyvinylpyrrolidone, macrogol, and similar
compounds to the excipients exemplified above); disintegrators
(examples include similar compounds to the excipients exemplified
above, and chemically modified starches and celluloses such as
sodium crosscarmellose, sodium carboxymethylstarch and cross-linked
polyvinylpyrrolidone); stabilizers (examples include
paraoxybenzoates such as methylparaben and propylparaben, alcohols
such as chlorobutanol, benzyl alcohol and phenylethyl alcohol,
benzalkonium chloride, phenol derivatives such as phenol and
cresol, thimerosal, dehydroacetic acid, and sorbic acid),
corrigents (examples include sweeteners, souring agents and flavors
which are usually used) and diluents.
[0065] The amount of the pharmaceutical composition varies,
depending upon the symptom and age of the patient (warm blooded
animal, such as a human) and the administration route. It is,
however, desirable to orally administer the active ingredients in
an amount ranging from 0.01 mg/kg body weight. (preferably 0.1
mg/kg body) as a lower limit to 100 mg/kg body weight (preferably
50 mg/kg body weight) as an upper limit once. While it is desirable
to intravenously administer it in an amount ranging from 0.01 mg/kg
body weight (preferably 0.05 mg/kg body weight) as a lower limit to
100 mg/kg body weight (preferably 50 mg/kg body weight) as an upper
limit once. In either case, the active ingredients are preferably
administered once to several times a day.
[0066] In the prophylactic and therapeutic agent for glaucoma
according to the present invention, a pharmaceutical composition
for separate or successive use of the angiotensin II antagonist and
at least one compound selected from the adrenaline receptor
blockers, prostaglandins and carbonic anhydrase inhibitors can be
prepared by individually formulating the compounds serving as
active ingredients (that is, angiotensin II antagonist and at least
one compound selected from the adrenaline receptor blockers,
prostaglandins and carbonic anhydrase inhibitors). The formulation
can be carried out in accordance with the above-described methods.
At this time, these formulations may be in the same form or a
different form. Forms suitable for topical application to the eyes
are especially preferred.
[0067] The present invention will hereinafter be described in
further detail by Examples. It should however be borne in mind that
the present invention is not limited to or by them.
EXAMPLES
Example 1
[0068] Using New Zealand White Rabbits having body weights of 2 to
3 kg, ocular hypertension models were prepared in accordance with
the method of Kurihara, et al. (Jpn. J. Ocular Pharmacology, 4,
62-64(1990)) and the intraocular pressure lowering action of the
test compounds was investigated.
[0069] Described specifically, the rabbits were maintained under
general anesthesia and their intraocular pressure was measured
using a tonometer ("Alcon Applanation Pneumatonography";
manufactured by Alcon). After instillation of local anesthetics
into the eyes of the rabbits, 0.1 ml of a 5% sodium chloride
solution were injected into their vitreous bodies through a 30
gauge needle. An increase in the intraocular pressure was confirmed
30 minutes after injection, followed by administration of 50 .mu.l
of an eye drop solution containing the test compound. Their
intraocular pressure was then measured for 2 hours at intervals of
30 minutes (single administration test).
[0070] In the combined administration test, after confirmation of
an increase in the intraocular pressure, 50 .mu.l of the solution
of the first test compound was administered, followed by the
administration of the same amount of the solution of the second
test compound after 5 minutes. After the second administration, the
intraocular pressure was measured for 2 hours at intervals of 30
minutes.
[0071] The below-described compound A was dissolved in a suitable
amount of an sodium hydroxide solution and this solution was used
as a test compound. With regards to the below-described compounds B
to E, commercially available eye drops were employed as the test
compound. 7
[0072] Compound B: timolol maleate
[0073] Compound C: isopropyl unoprostone
[0074] Compound D: latanoprost
[0075] Compound E: dorzolamide hydrochloride
[0076] When Compound A which is an angiotensin II antagonist was
administered in combination with any one of Compounds B, C, D and
E, intraocular pressure lowering action was potentiated.
Example 2
Intraocular Pressure Lowering Action (2)
[0077] Using a tonometer ("Alcon Applanation Pneumatonography;
manufactured by Alcon), the intraocular pressure of each of New
Zealand White Rabbits having body weights of 2 to 3 kg was measured
(without anesthesia), followed by administration of 50 .mu.l of a
test compound in the form of eye drops. The intraocular pressure
was then measured for 4 hours at intervals of one hour (single
administration test).
[0078] In the combined administration test, after measurement of
the intraocular pressure, 50 .mu.l of the first test compound
solution was administered, followed by the administration of the
same amount of the second test compound solution after 5 minutes.
After the second administration, the intraocular pressure was
measured for 4 hours at intervals of 1 hour.
[0079] Also in this Example, the same test compounds as described
in Example 1 were employed.
[0080] When Compound A which is an angiotensin II antagonist was
administered in combination with any one of Compounds B, C, D and
E, intraocular pressure lowering action was potentiated.
Example 3
Intraocular Pressure Lowering Test (3)
[0081] After the measurement of the intraocular pressure as in
Example 2, 50 .mu.l of a solution of test compound 1 was instilled
into the eyes, followed by administration of the same amount of the
solution of test compound 2 after 5 minutes. Four hours after the
second administration, the intraocular pressure was measured and
the change ratio of the intraocular pressure was determined by the
below-described equation:
[0082] The change ratio of intraocular pressure (%)=[(intraocular
pressure after administration of eye drops-intraocular pressure
before administration of eye drops)/intraocular pressure before
administration of eye drops].times.100.
[0083] In this Example, the same test compounds as Example 1 were
employed. The results are shown below in Tables 1 and 2.
1TABLE 1 Combined administration of Compound A and Compound C
Change ratio (%) of Test compound 1 Test compound 2 intraocular
pressure Physiological saline Physiological saline 7.3 .+-. 3.7
Compound A (4%) Physiological saline 11.4 .+-. 5.5 Physiological
saline Compound C (0.12%) -2.4 .+-. 9.1 Compound A (4%) Compound C
(0.12%) -15.3 .+-. 4.5
[0084]
2TABLE 2 Combined administration of compound A and Compound D
Change ratio (%) of Test compound 1 Test compound 2 intraocular
pressure Physiological saline Physiological saline 1.7 .+-. 4.4
Compound A (4%) Physiological saline 11.5 .+-. 4.1 Physiological
saline Compound D(0.005%) 17.2 .+-. 8.8 Compound A (4%) Compound
D(0.005%) -8.2 .+-. 4.7
[0085] As is apparent from the Tables 1 and 2, synergistic
intraocular pressure lowering action was observed when the
angiotensin II antagonist (Compound A) and the prostaglandin
(Compound C or D) were administered in combination.
Example 4
Intraocular Pressure Lowering Test (4)
[0086] An ocular hypertension model was made as in Example 1. After
confirmation of an increase in the intraocular pressure, 50 .mu.l
of a test compound 1 was instilled to the eyes, followed by
application of the same amount of a test compound 2 into the eyes
after 5 minutes. After this second administration, the intraocular
pressure was measured for 2 hours at intervals of 1 hour.
Intraocular pressure lowering was determined by the below-described
equation.
[0087] Decrease in intraocular pressure (mmHg)=(intraocular
pressure after instillation of a compound group-intraocular
pressure before instillation of the compound group)-(intraocular
pressure after instillation of a control group-intraocular pressure
before instillation of the control group)
[0088] The term "control group" in the above-described formula
means a group to which physiological saline was administered to the
eyes instead of each of the test compound 1 and test compound 2.
Groups other than this control group are a compound group.
[0089] Also in this Example, the same test compounds as described
in Example 1 were employed. The results are shown below in Table
3.
3TABLE 3 Combined administration of Compound A with Compound B
Decrease in intraocular pressure (mmHg) Time after instillation
(min) Test compound 1 Test compound 2 0 60 120 Physiological
Physiological 0 0 0 saline saline Compound A Physiological 0.0 .+-.
2.1 -1.7 .+-. 2.2 -3.4 .+-. 1.7 (1%) saline Physiological Compound
B 0.0 .+-. 1.5 -2.0 .+-. 3.5 -1.9 .+-. 3.2 saline (0.25%) Compound
A Compound B 0.0 .+-. 0.9 -5.0 .+-. 2.4 -7.4 .+-. 1.8 (1%)
(0.25%)
[0090] As is apparent from Table 3, stronger intraocular pressure
lowering action was observed when the angiotensin II antagonist
(Compound A) was administered in combination with timolol maleate
(Compound B).
FORMULATION EXAMPLES
Formulation Example 1
An Eye Drop Containing Compound A and Timolol Maleate
[0091]
4 Compound A 0.001 g Timolol maleate 0.001 g Disodium phosphate
0.716 g Monosodium phosphate 0.728 g Sodium chloride 0.400 g Methyl
p-hydroxybenzoate 0.026 g Propyl p-hydroxybenzoate 0.014 g
Sterilized purified water q.s. Sodium hydroxide q.s. Total amount
100 ml
Formulation Example 2
Combination of an Eye Drop of Compound A and an Eye Drop of
Isopropyl Unoprostone
[0092]
5 Compound A 0.002 g Disodium phosphate 0.716 g Monosodium
phosphate 0.728 g Sodium chloride 0.400 g Methyl p-hydroxybenzoate
0.026 g Propyl p-hydroxybenzoate 0.014 g Sterilized purified water
q.s. Sodium hydroxide q.s. Total amount 100 ml
[0093]
6 Isopropyl unoprostone 0.002 g Disodium phosphate 0.716 g
Monosodium phosphate 0.728 g Sodium chloride 0.400 g Methyl
p-hydroxybenzoate 0.026 g Propyl p-hydroxybenzoate 0.014 g
Sterilized purified water q.s. Sodium hydroxide q.s. Total amount
100 ml
Formulation Example 3
Combination of an Eye Drop of Compound A and an Eye Drop of
Latanoprost
[0094]
7 Compound A 0.002 g Disodium phosphate 0.716 g Monosodium
phosphate 0.728 g Sodium chloride 0.400 g Methyl p-hydroxybenzoate
0.026 g Propyl p-hydroxybenzoate 0.014 g Sterilized purified water
q.s. Sodium hydroxide q.s. Total amount 100 ml
[0095]
8 Latanoprost 0.002 g Disodium phosphate 0.716 g Monosodium
phosphate 0.728 g Sodium chloride 0.400 g Methyl p-hydroxybenzoate
0.026 g Propyl p-hydroxybenzoate 0.014 g Sterilized purified water
q.s. Sodium hydroxide q.s. Total amount 100 ml
[0096] Administration of an angiotensin II antagonist in
combination with at least one compound selected from an adrenaline
receptor blocker, a prostaglandin and a carbonic anhydrase
inhibitor makes it possible to attain an excellent intraocular
pressure lowering effect. The pharmaceutical composition of the
present invention is therefore useful as a prophylactic or
therapeutic agent for glaucoma.
* * * * *